The objective of this paper is to evaluate persistence with treatmentand resources allocation in antihypertensive pharmacotherapy in a’real world' population. An administrative database listing all purchaseddrugs was used to perform a longitudinal analysis. The study includedall new users over 20 years of age receiving a first prescriptionfor amlodipine, atenolol, fosinopril, indapamide, or losartan, inan enrolment period of 12 months. The follow-up period lasted 12months. According to prescriptions dynamics, subjects were classifiedas same therapy, combination, switching, interruption and occasionalutilization. The 34.9% study cohort, persisted with treatment (21.1%on same therapy, 4.7% on combination and 9.1% on switching), while65.1% did not persist (10.9% on interruption and 54.2% on occasionaluse). The overall drug cost accounted for persistent (69.0%) andnonpersistent subjects (31.0%). The annual average cost ranged fromε32.80 for occasional users to ε274.69 for those in combination.In clinical practice, a high percentage of patients do not receiveadequate antihypertensive therapy, since the 65.1% of subjects didnot persist with treatment. This results in a level of pharmaceuticalexpenditure that cannot be considered appropriately allocated.